A Phase 2 interventional study of M1095 (Sonelokimab) and Placebo in Psoriasis, sponsored by Bond Avillion 2 Development LP. Completed at 60 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-03.
Sponsored by Bond Avillion 2 Development LP · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 299 studies in Psoriasis with a site in Germany — 13 open to participants now, 30 under way, 15 of them phase 3. Psoriasis · Germany.
Among the 299 studies in Psoriasis with a site in Germany, this one is the 97th largest by enrollment of the 260 interventional ones that give a count, is one of 28 that started in 2018, is one of 74 in phase 2, and was the 185th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →13 of the 299 studies in Psoriasis with a site in Germany are open now. Recruiting first, the newest first:
Takeda · Sites in Germany, United States, China and 4 more countries
Ages 4–17
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 13 more countries
Ages 12–17
UCB Biopharma SRL · Sites in Germany, United States, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 22 more countries
Ages 40+
LEO Pharma · Sites in Germany, United States, Canada and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
299 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 83 · Phase 3 122 · Phase 4 23
First in 2000; this study’s year is marked. 28 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 313 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 196 across the 260 interventional studies, 588 across the 39 observational. Of the 264 that completed or were terminated, 160 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
274 of 299 have an industry lead sponsor. The 10 most frequent:
Bond Avillion 2 Development LP is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Bond Avillion 2 Development LP has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
2 of the studies in Psoriasis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013201LEO PharmaA 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | 2027-06-04 |
| NCT03886246LEO PharmaEffisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 299 studies in Psoriasis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Main):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
Drug: M1095 (Sonelokimab)
M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
Drug: M1095 (Sonelokimab)
M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
Drug: M1095 (Sonelokimab)
M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
Drug: M1095 (Sonelokimab)
Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
Drug: M1095 (Sonelokimab) · Drug: Placebo
Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
Drug: Secukinumab
M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
Also known as: Sonelokimab
Placebo contains no active drug.
Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
Also known as: Cosentyx®
Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1
The primary endpoint is achievement of an IGA score of 0 or 1 at Week 12, with an IGA reduction of at least 2 points from baseline. The percentage of subjects in the Intent to Treat (ITT) Analysis Set with an IGA score of 0 or 1 at Week 12 will be used to compare treatment arms. IGA is the Investigator's Global Assessment of the extent of psoriasis, with 0 = clear of psoriasis, 1 = almost clear, 2 = mild psoriasis, 3 = moderate psoriasis, and 4 = severe psoriasis (the worst assessment on this scale). Higher scores in the IGA indicate a worse outcome.
Time frame: Week 12, as compared to Week 0 (baseline)
Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 100% (i.e. Clear of Psoriasis)
PASI 100, i.e. a subject's psoriasis has completely cleared at Week 12, compared to baseline.
Time frame: Week 12, as compared to Week 0 (baseline)
Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 90% (i.e. a 90% Improvement in Psoriasis)
PASI 90, i.e. a subject's psoriasis has cleared by 90% at Week 12, compared to baseline
Time frame: Week 12, as compared to baseline
Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 75% (i.e. a 75% Improvement in Psoriasis)
PASI 75, i.e. a subject's psoriasis has cleared by 75% at Week 12, compared to baseline
Time frame: Week 12, as compared to Week 0 (baseline)
Subjects were adults aged 18-75 years with stable, moderate to severe plaque type psoriasis for \>6 months prior to randomisation, and who were candidates for systemic biologic therapy.
| Milestone | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab |
|---|---|---|---|---|---|---|
| Started | 52 | 52 | 53 | 51 | 52 | 53 |
| Completed | 52 | 51 | 50 | 49 | 49 | 51 |
| Not completed | 0 | 1 | 3 | 2 | 3 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab |
|---|---|---|---|---|---|---|
| Started | 52 | 51 | 50 | 49 | 49 | 51 |
| Completed | 52 | 51 | 49 | 47 | 47 | 51 |
| Not completed | 0 | 0 | 1 | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 1 | 0 | 0 |
| Milestone | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab |
|---|---|---|---|---|---|---|
| Started | 52 | 51 | 49 | 47 | 47 | 51 |
| Completed | 51 | 48 | 45 | 43 | 46 | 49 |
| Not completed | 1 | 3 | 4 | 4 | 1 | 2 |
| Withdrew: Adverse event | 1 | 1 | 3 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 2 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 |
The primary endpoint is achievement of an IGA score of 0 or 1 at Week 12, with an IGA reduction of at least 2 points from baseline. The percentage of subjects in the Intent to Treat (ITT) Analysis Set with an IGA score of 0 or 1 at Week 12 will be used to compare treatment arms. IGA is the Investigator's Global Assessment of the extent of psoriasis, with 0 = clear of psoriasis, 1 = almost clear, 2 = mild psoriasis, 3 = moderate psoriasis, and 4 = severe psoriasis (the worst assessment on this scale). Higher scores in the IGA indicate a worse outcome.
| Participants | M1095 30mg | M1095 60mg | M1095 120mg - Normal Load Group | M1095 120mg - Augmented Load Group | Placebo | Secukinumab |
|---|---|---|---|---|---|---|
| Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 | 25 | 44 | 41 | 45 | 0 | 41 |
PASI 100, i.e. a subject's psoriasis has completely cleared at Week 12, compared to baseline.
| Participants | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab |
|---|---|---|---|---|---|---|
| Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 100% (i.e. Clear of Psoriasis) | 9 | 13 | 20 | 17 | 0 | 15 |
PASI 90, i.e. a subject's psoriasis has cleared by 90% at Week 12, compared to baseline
| Participants | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab |
|---|---|---|---|---|---|---|
| Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 90% (i.e. a 90% Improvement in Psoriasis) | 19 | 34 | 37 | 39 | 0 | 34 |
PASI 75, i.e. a subject's psoriasis has cleared by 75% at Week 12, compared to baseline
| Participants | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab |
|---|---|---|---|---|---|---|
| Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 75% (i.e. a 75% Improvement in Psoriasis) | 34 | 46 | 45 | 46 | 0 | 48 |
Collected over Adverse events were collected from the signing of the informed consent form i.e. the start of the screening period (Week -4) through to the end of the study (Week 52).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Week 0 to Week 12) | 0/52 (0%) | 1/52 (1.9%) | 11/52 (21.2%) |
| M1095 30mg (Week 0 to Week 12) | 0/52 (0%) | 2/52 (3.8%) | 13/52 (25%) |
| M1095 60 mg (Week 0 to Week 12) | 0/52 (0%) | 1/52 (1.9%) | 16/52 (30.8%) |
| M1095 120mg - Normal Load Group (Week 0 to Week 12) | 0/53 (0%) | 1/53 (1.9%) | 18/53 (34%) |
| M1095 120mg - Augmented Load Group (Week 0 to Week 12) | 0/51 (0%) | 1/51 (2%) | 15/51 (29.4%) |
| Secukinumab (Week 0 to Week 12) | 0/53 (0%) | 0/53 (0%) | 14/53 (26.4%) |
| M1095 - All Participants (Week 0 to Week 12 ) | 0/208 (0%) | 5/208 (2.4%) | 62/208 (29.8%) |
| M1095 - All Participants (Week 12 to Week 52) | 1/251 (0.4%) | 12/251 (4.8%) | 57/251 (22.7%) |
| Secukinumab (Week 12 to Week 52) | 0/51 (0%) | 2/51 (3.9%) | 16/51 (31.4%) |
| Event | Placebo (Week 0 to Week 12) | M1095 30mg (Week 0 to Week 12) | M1095 60 mg (Week 0 to Week 12) | M1095 120mg - Normal Load Group (Week 0 to Week 12) | M1095 120mg - Augmented Load Group (Week 0 to Week 12) | Secukinumab (Week 0 to Week 12) | M1095 - All Participants (Week 0 to Week 12 ) | M1095 - All Participants (Week 12 to Week 52) | Secukinumab (Week 12 to Week 52) |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/52 | 0/52 | 0/52 | 0/53 | 1/51 | 0/53 | 1/208 | 0/251 | 0/51 |
| Infectious pleural effusionInfections and infestations | 0/52 | 0/52 | 0/52 | 0/53 | 0/51 | 0/53 | 0/208 | 0/251 | 1/51 |
| Oesophageal candidiasisInfections and infestations | 0/52 | 0/52 | 0/52 | 0/53 | 0/51 | 0/53 | 0/208 | 0/251 | 1/51 |
| PneumoniaInfections and infestations | 0/52 | 0/52 | 0/52 | 0/53 | 1/51 | 0/53 | 1/208 | 0/251 | 1/51 |
| Forearm fractureInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/52 | 0/53 | 0/51 | 0/53 | 1/208 | 0/251 | 0/51 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/52 | 1/52 | 0/52 | 0/53 | 0/51 | 0/53 | 1/208 | 0/251 | 0/51 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/52 | 1/52 | 0/52 | 0/53 | 0/51 | 0/53 | 1/208 | 0/251 | 0/51 |
| HypertensionVascular disorders | 1/52 | 0/52 | 0/52 | 0/53 | 0/51 | 0/53 | 0/208 | 0/251 | 0/51 |
| Renal colicRenal and urinary disorders | 0/52 | 0/52 | 0/52 | 1/53 | 0/51 | 0/53 | 1/208 | 0/251 | 0/51 |
| Atrial fibrillationCardiac disorders | 0/52 | 0/52 | 0/52 | 0/53 | 0/51 | 0/53 | 0/208 | 2/251 | 0/51 |
| Event | Placebo (Week 0 to Week 12) | M1095 30mg (Week 0 to Week 12) | M1095 60 mg (Week 0 to Week 12) | M1095 120mg - Normal Load Group (Week 0 to Week 12) | M1095 120mg - Augmented Load Group (Week 0 to Week 12) | Secukinumab (Week 0 to Week 12) | M1095 - All Participants (Week 0 to Week 12 ) | M1095 - All Participants (Week 12 to Week 52) | Secukinumab (Week 12 to Week 52) |
|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/52 | 4/52 | 11/52 | 9/53 | 4/51 | 6/53 | 28/208 | 26/251 | 7/51 |
| PruritusSkin and subcutaneous tissue disorders | 2/52 | 3/52 | 4/52 | 3/53 | 4/51 | 1/53 | 14/208 | 6/251 | 1/51 |
| Upper respiratory tract infectionInfections and infestations | 1/52 | 1/52 | 3/52 | 3/53 | 2/51 | 3/53 | 9/208 | 12/251 | 3/51 |
| Oral candidiasisInfections and infestations | 0/52 | 0/52 | 1/52 | 2/53 | 3/51 | 0/53 | 6/208 | 13/251 | 0/51 |
| HeadacheNervous system disorders | 1/52 | 0/52 | 3/52 | 3/53 | 1/51 | 3/53 | 7/208 | 3/251 | 1/51 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/52 | 3/52 | 0/52 | 1/53 | 2/51 | 0/53 | 6/208 | 5/251 | 2/51 |
| HypertensionVascular disorders | 2/52 | 3/52 | 1/52 | 0/53 | 2/51 | 1/53 | 6/208 | 5/251 | 2/51 |
| Age, Continuous(years) | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab | Total |
|---|---|---|---|---|---|---|---|
| Mean | 48.2 ± 13.4 | 46.9 ± 12.3 | 44.1 ± 13.1 | 43.2 ± 13.2 | 45.9 ± 12.9 | 47.5 ± 13.8 | 46.0 ± 13.1 |
| Sex: Female, Male(Participants) | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab | Total |
|---|---|---|---|---|---|---|---|
| Female | 36 | 38 | 43 | 34 | 39 | 38 | 228 |
| Male | 16 | 14 | 10 | 17 | 13 | 15 | 85 |
| Ethnicity (NIH/OMB)(Participants) | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 3 | 2 | 1 | 2 | 15 |
| Not Hispanic or Latino | 48 | 49 | 50 | 49 | 51 | 51 | 298 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 2 | 1 | 8 | 2 | 6 | 3 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 2 | 2 | 1 | 6 |
| White | 49 | 48 | 45 | 47 | 44 | 49 | 282 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Region of Enrollment(participants) | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab | Total |
|---|---|---|---|---|---|---|---|
| Canada | 7 | 9 | 11 | 9 | 12 | 11 | 59 |
| Hungary | 6 | 8 | 6 | 4 | 5 | 4 | 33 |
| United States | 10 | 7 | 6 | 5 | 3 | 5 | 36 |
| Czechia | 13 | 14 | 13 | 8 | 16 | 16 | 80 |
| Poland | 8 | 8 | 7 | 13 | 5 | 10 | 51 |
| Bulgaria | 7 | 4 | 8 | 10 | 9 | 5 | 43 |
| Germany | 1 | 2 | 2 | 2 | 2 | 2 | 11 |
| Height (cm)(centimetres) | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab | Total |
|---|---|---|---|---|---|---|---|
| Mean | 173 ± 10.4 | 173 ± 9.60 | 174 ± 9.89 | 173 ± 11.2 | 173 ± 10.1 | 172 ± 9.98 | 173 ± 10.2 |
| Weight at baseline (kg)(kilograms) | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab | Total |
|---|---|---|---|---|---|---|---|
| Mean | 92.0 ± 19.0 | 91.5 ± 20.6 | 89.0 ± 18.3 | 93.0 ± 22.6 | 91.3 ± 24.1 | 90.3 ± 22.4 | 91.2 ± 21.1 |
| Prior biological use (actual)(Participants) | M1095 30mg | M1095 60mg | M1095 120mg - Regimen 1 | M1095 120mg - Regimen 2 | Placebo / M1095 120mg | Secukinumab | Total |
|---|---|---|---|---|---|---|---|
| Yes | 9 | 10 | 9 | 7 | 8 | 7 | 50 |
| No | 43 | 42 | 44 | 44 | 44 | 46 | 263 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Jun 2019, 10 months.
Results were first posted in Aug 2021, 2 years 1 month after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonelokimab
Bond Avillion 2 Development LP